J. F. Allilaire, Angoisse psychotique et angoisse névrotique. Différence qualitative ou différence quantitative ?, L'Encéphale, vol.9, pp.211-217, 1983.

. Apa, American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia, 2004.

D. Bailly, M. Viellard, and H. Duverger, Un diagnostic méconnu : la schizophrénie chez l'enfant, Ann Med Psychol, vol.161, pp.652-661, 2003.

T. Barnes, Pharmacological strategies for relapse prevention in schizophrenia, Psychiatry, vol.3, pp.37-40, 2004.

F. J. Baylé, M. O. Krebs, and C. Epelbaum, Clinical features of panic attacks in schizophrenia, Eur Psychiatry, vol.16, pp.349-53, 2001.

F. J. Baylé, P. M. Llorca, and J. P. Olié, Anxiété et schizophrénie : situation actuelle, Ann Med Psychol, vol.158, pp.741-750, 2000.

I. Berman, B. L. Sapers, and H. H. Chang, Treatment of obsessive-compulsive symptoms in schizophrenic patients with clomipramine, J Clin Psychopharmacol, vol.15, pp.206-216, 1995.

P. C. Bermanzohn, L. Porto, and P. B. Arlow, At issue: hierarchical diagnosis in chronic schizophrenia: a clinical study of co-occurring syndromes, Schizophr Bull, vol.26, pp.517-542, 2000.

O. Blanc, Validation of a new anxiety scale in schizophrenia (EAS scale), Schizophr Res, vol.102, pp.224-1224, 2008.

J. J. Blanchard, K. T. Muser, and A. S. Bellack, Anhedonia, positive and negative affect and social functioning in schizophrenia, Schizophr Bull, vol.24, pp.413-437, 1998.

R. C. Bland, S. C. Newman, and H. Orn, Schizophrenia: lifetime comorbidity in a community sample, Acta Psychiatr Scand, vol.75, pp.383-91, 1987.

O. Blin, J. M. Azorin, and P. Bouhours, Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients, J Clin Psychopharmacol, vol.16, pp.38-44, 1996.

O. Blin, J. M. Azorin, and Y. Lecrubier, Psychotic Anxiety Scale (PAS) : évaluation de la fidélité intercotateurs et analyse factorielle des correspondances, L'Encéphale, vol.15, pp.543-550, 1989.

M. Bourin, E. Dailly, and M. Hascöet, Preclinical and clinical pharmacology of cyamemazine: anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome, CNS Drug Rev, vol.10, pp.219-248, 2004.

R. J. Braga, M. V. Mendlowicz, and R. P. Marrocos, Anxiety disorders in outpatients with schizophrenia: prevalence and impact on the subjective quality of life, J Psychiatric Res, vol.39, pp.409-423, 2005.

R. J. Braga, G. Petrides, and I. Figueira, Anxiety disorders in schizophrenia, Comp Psychiatry, vol.45, pp.460-468, 2004.

P. F. Buckley, Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials, Curr Med Res Opinion, vol.20, pp.1357-63, 2004.

C. Y. Chen, C. Y. Liu, and Y. Y. Yang, Correlation of panic attacks and hostility in chronic schizophrenia, Psychiatry Clin Neurosci, vol.55, pp.383-390, 2001.

S. J. Cosoff and R. J. Hafner, The prevalence of comorbid anxiety in schizophrenia, schizoaffective disorder and bipolar disorder, Aust N Z J Psychiatry, vol.32, pp.67-72, 1998.

J. L. Cutler and S. G. Siris, Panic-like'' symptomatology in schizophrenic and schizoaffective patients with post-psychotic depression: observations and implications, Comp Psychiatry, vol.32, pp.465-73, 1991.

L. W. Davis, A. M. Strasburger, and L. F. Brown, Mindfulness: an intervention for anxiety in schizophrenia, J Psychosoc Nurs Ment Health Serv, vol.45, pp.23-32, 2007.

M. Dossenbach, M. Jakovljevicz, and V. Folnegovic, Olanzapine versus fluphenazine -6 weeks treatment of anxiety symptoms during acute schizophrenia, Schizophr Res, vol.29, pp.203-1203, 1998.

R. A. Emsley, P. P. Oosthuizen, and A. F. Joubert, Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder, J Clin Psychiatry, vol.60, pp.747-51, 1999.

R. Gaillard, A. Ouanas, and C. Spadone, Benzodiazé-pines et schizophrénie, revue de la littérature, L'Encéphale, vol.32, pp.1003-1013, 2006.

M. Garvey, R. Noyes, and D. Anderson, Examination of comorbid anxiety in psychiatric inpatients, Comp Psychiatry, vol.32, pp.277-82, 1991.

C. Gury, C. Fabre, and A. Hameg, Prescription d'antipsychotiques en milieu hospitalier spécialisé, Inf Psychiatr, vol.82, pp.1-7, 2006.
DOI : 10.3917/inpsy.8206.0503

J. D. Huppert and T. E. Smith, Longitudinal analysis of subjective quality of life in schizophrenia: anxiety as the best symptom predictor, J Nerv Ment Dis, vol.189, pp.669-75, 2001.

J. D. Huppert and T. E. Smith, Anxiety and schizophrenia: the interaction of subtypes of anxiety and psychotic symptoms, CNS Spectr, vol.10, pp.721-752, 2005.

J. D. Huppert, K. A. Weiss, and R. Lim, Quality of life in schizophrenia: contributions of anxiety and depression, Schizophr Res, vol.51, pp.171-80, 2001.

S. Kasper, Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia, Depress Anxiety, vol.20, pp.44-51, 2004.

K. S. Kendler, T. J. Gallagher, and J. M. Abelson, Lifetime prevalence, demographic risk factors, and diagnostic validity of non-affective psychosis as assessed in a US community sample. The National Comorbidity Survey, Arch Gen Psychiatry, vol.53, pp.1022-1053, 1996.

M. S. Keshavan, V. A. Diwadkar, and D. M. Montrose, Premorbid indicators and risk for schizophrenia: a selective review and update, Schizophr Res, vol.79, pp.45-57, 2005.

C. Lançon, V. Aghababian, and P. M. Llorca, Factorial structure of the Positive and Negative Syndrome Scale (PANSS): a forced five-dimensional factor analysis, Acta Psychiatr Scand, vol.97, pp.369-76, 1998.

P. M. Llorca and . La-schizophrénie, , 2004.

H. Lôo, , pp.41-57, 1977.

P. H. Lysaker and J. Hammersley, Association of delusions and lack of cognitive flexibility with social anxiety in schizophrenia spectrum disorders, Schizophr Res, vol.86, pp.147-53, 2006.

N. Muller, Mechanisms of relapse prevention in schizophrenia, Pharmacopsychiatry, vol.37, pp.141-148, 2004.

R. M. Norman, A. K. Malla, and L. Cortese, Aspects of dysphoria and symptoms of schizophrenia, Psychol Med, vol.28, pp.1433-1474, 1998.

K. H. Nuechterlein, M. Dawson, and J. Ventura, The vulnerability/stress model of schizophrenic relapse: a longitudinal study, Acta Psychiatr Scand, vol.382, pp.58-64, 1994.

P. Nuss, P. M. Llorca, and C. Lançon, Activité anxiolytique de la cyamémazine : rôle des récepteurs sérotoninergiques, Inf Psychiatr, vol.83, pp.595-601, 2007.

S. Pallanti, L. Quercioli, and E. Hollander, Social anxiety in outpatients with schizophrenia: a relevant cause of disability, Am J Psychiatry, vol.161, pp.53-61, 2004.

M. Poyurovsky, C. Fuchs, and A. Weizman, Obsessive-compulsive disorder in patients with first-episode schizophrenia, Am J Psychiatry, vol.156, 1998.

F. Radat, Cyamémazine : traitement symptomatique des dimensions anxieuses, impulsives et agressives, Inf Psychiatr, vol.10, pp.967-975, 1995.

I. Reznik and P. Sirota, Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics, J Clin Psychopharmacol, vol.20, pp.410-416, 2000.

J. L. Romain, P. Dermain, and P. Greslé, Efficacité de l'acétate de zuclopenthixol sur l'anxiété psychotique évaluée lors d'une étude ouverte, L'Encéphale, vol.22, pp.280-286, 1996.

M. Sannomiya, H. Katsu, and K. Nakayama, A clinical study of emergent anxiety in neuroleptic-naïve, first-episode schizophrenia patients following treatment with risperidone, Seishin Shinkeigaku Zasshi, vol.105, pp.643-58, 2003.

S. Sevy, K. Nathanson, and H. Visweswaraiah, The relationship between insight and symptoms in schizophrenia, Compr Psychiatry, vol.45, pp.16-25, 2004.

P. Tibbo, J. Swainson, and P. Chue, Prevalence and relationship to delusions and hallucinations of anxiety disorders in schizophrenia, Depress Anxiety, vol.17, pp.65-72, 2003.

L. White, P. D. Harvey, and L. Opler, Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale, Psychopathology, vol.30, pp.263-74, 1997.